Skip to Main Content
TRC_Prescriber's Letter NEW
Menu
    • Products
      • Hospital Pharmacist's Letter
      • Hospital Pharmacy Technician's Letter
      • Learning Management Portal
      • NatMed Advisor
      • NatMed Pro
      • NetCE All Access: APRN
      • NetCE All Access: MD
      • NetCE All Access: PA
      • NetCE All Access: RN
      • Pharmacist's Letter
      • Pharmacist's Letter Canada
      • Pharmacy Technician's Letter
      • Pharmacy Technician's Letter Canada
      • Prescriber Insights: APRN
      • Prescriber Insights: MD
      • Prescriber Insights: PA
      • Prescriber's Letter
      • RxAdvanced
      • RxSelect

    Subscribe Login
  • Home
  • Letter
    • Current Issue
    • Past Issues
    • Suggest a Topic
  • Browse
    • Subject
    • Charts
    • COVID-19 Resources
    • Diabetes Resources
    • Immunization Resources
    • Natural Medicines Resources
    • Journal Club
  • Drug Charts
    • First-Time Generics
    • New Drugs
  • Help
    • User Support
    • Contact Us
  • GO TO CE/CME & Training

Upgrade Your Browser

We no longer support this version of your browser. We recommend that you upgrade to the latest version of Internet Explorer, Firefox, Chrome or Safari to improve your security and experience using this website.

Return to the course you were viewing

All Access is Now Available: Meet your CE/CME requirements with unlimited access to hundreds of hours, including state mandated courses, with All Access. Learn More
COMING SOON: In the next few weeks, Prescriber's Letter is becoming Prescriber Insights, with all the high-quality content you trust, but delivered in profession-specific editions. As the updates push to your account, you will begin to see references to Prescriber Insights and a prompt to select your profession-specific edition.
  1. Home
  2. Browse
  3. Men's Health
  4. Benign Prostatic Hypertrophy
  5. Treatment

Treatment

  • Benign Prostatic Hypertrophy (34)
    • Drug Toxicity (13)
    • Treatment (28)
  • Erectile Dysfunction (57)
  • Infectious Diseases (30)
  • Infertility (5)
  • Resources (51)
  • Testosterone (35)
16 - 28 of 28 Results
Sort Results:
  • Title: Ascending (A-Z)
  • Date: Newest First
  • Date: Oldest First
Commentary: Possible Increased Risk of Aggressive Prostate Cancer with Finasteride and Dutasteride August 2011
Article: Flomax (tamsulosin) is the first SELECTIVE alpha-blocker for benign prostatic hyperplasia (BPH) to go generic April 2010
Commentary: First Generic Flomax (Tamsulosin) Approved April 2010
Article: whether saw palmetto is effective for benign prostatic hyperplasia (BPH) March 2010
Other: Natural Medicines in the Clinical Management of Benign Prostatic Hyperplasia March 2010
Article: when to use 5-alpha-reductase inhibitors (Proscar, Avodart) or PSA screening to prevent prostate cancer July 2009
Guideline: American College of Preventative Medicine. Prostate cancer screening. July 2009
Commentary: Controversies in Prostate Cancer: Role of PSA Testing and 5-Alpha-Reductase Inhibitors July 2009
Guideline: U.S. Preventive Services Task Force. Prostate cancer screening. July 2009
Guideline: Use of 5-Alpha-Reductase Inhibitors to Prevent Prostate Cancer July 2009
Article: Rapaflo (silodosin), a new selective alpha-blocker for benign prostatic hyperplasia (BPH) May 2009
Article: Avodart (dutasteride) with Flomax (tamsulosin) for benign prostatic hyperplasia (BPH) August 2008
Commentary: Combination Therapy for Benign Prostatic Hyperplasia (BPH) August 2008
  • « Prev
  • 1
  • 2
  • About Us
  • Our Mission
  • Our Team
  • Testimonials
  • Careers
  • Newsroom
  • Products
  • Pharmacist Solutions
  • Prescriber Solutions
  • Hospital Solutions
  • Retail Solutions
  • Group Practice Solutions
  • Support & Policies
  • Contact Us
  • Access Agreement
  • Privacy Policy

The contents of this website are not intended to be a substitute for professional medical advice, diagnosis, or treatment. See additional information.

© Therapeutic Research Center. All Rights Reserved